½ÃÀ庸°í¼­
»óǰÄÚµå
1324913

¼¼°èÀÇ Àΰø Ÿ¾× ½ÃÀå : ÇöȲ ºÐ¼® ¹× ¿¹Ãø(2022-2028³â)

Artificial Saliva Market: Current Analysis and Forecast (2022-2028)

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: UnivDatos Market Insights Pvt Ltd | ÆäÀÌÁö Á¤º¸: ¿µ¹® 142 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

ÀÇ»ç´Â ±¸°­ °ÇÁ¶ÁõÀ» À¯¹ßÇÏ´Â °ÍÀ¸·Î ¾Ë·ÁÁø ÁøÅëÁ¦ ¹× È­ÇÐ ¿ä¹ý°ú °°Àº ¾à¹° ¹× ÀÇÇÐÀû Ä¡·á¿Í ÇÔ²² Àΰø Ÿ¾× »ç¿ëÀ» ±ÇÀåÇÒ ¼ö ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ¹Ì±¹ ±¹¸³¾Ï¿¬±¸¼Ò(NIH)¿¡ µû¸£¸é 2022³â ¹Ì±¹¿¡´Â 1,810¸¸ ¸íÀÇ ¾Ï »ýÁ¸ÀÚ°¡ ÀÖÀ» °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. ÀÌ´Â Àüü Àα¸ÀÇ ¾à 5.4%¿¡ ÇØ´çÇϸç 2032³â¿¡´Â 24.4% Áõ°¡ÇÑ 2,250¸¸ ¸íÀ¸·Î ´Ã¾î³¯ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Àΰø Ÿ¾×(Artificial Saliva) ½ÃÀåÀº ¾Ï ȯÀÚÀÇ ¿¬ÇÏ Àå¾Ö À¯º´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¾à 13%ÀÇ ²ÙÁØÇÑ ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ ¼±Áø±¹°ú °³¹ß µµ»ó±¹ ¸ðµÎ¿¡¼­ ±¸°­ Áúȯ¿¡ ´ëÇÑ °ª ºñ½Ñ Ä¡·á¹ý°ú °¡Ã³ºÐ ¼Òµæ Áõ°¡ ¹× 1 Àδç ÁöÃâ Áõ°¡´Â ¿¹Ãø ±â°£ µ¿¾È ½ÃÀåÀÇ ¼ºÀåÀ» ÁÖµµÇÕ´Ï´Ù.

Á¦Ç° À¯Çü¿¡ µû¶ó ½ÃÀåÀº °æ±¸ ½ºÇÁ·¹ÀÌ, °æ±¸¾×, ³»º¹¾×, Á©, ºÐ¸»·Î ±¸ºÐµË´Ï´Ù. ¿¹Ãø ±â°£ Áß °¡Àå CAGRÀÌ ³ôÀº °æ±¸ ½ºÇÁ·¹ÀÌÀÔ´Ï´Ù. À̰ÍÀº ÁÖ·Î »ç¿ëÀÇ ¿ëÀ̼º, È¿À²¼º ¹× Àúºñ¿ëÀ¸·Î ÀÎÇÑ °ÍÀ̸ç, ÀÌ·¯ÇÑ ½ºÇÁ·¹ÀÌ´Â ±¸°­ °ÇÁ¶ »óÅÂÀÇ Ä¡·á¿¡ ÀϹÝÀûÀ¸·Î »ç¿ëµË´Ï´Ù. ¶ÇÇÑ ÁÖ¿ä ±â¾÷ÀÇ Á¦Ç° °³¹ß Áõ°¡°¡ ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀ» Áö¿øÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î ´º¸ß½ÃÄÚ °ø°ú´ëÇÐÀÌ Ã¢Á¶ÇÏ°í ¶óÀ̼±½º¸¦ ¹ÞÀº µ¶ÀÚ¹°ÁúÀÎ MycoDelens¿¡ ±âÃÊÇÑ ¸¶¿ì½º ½ºÇÁ·¹ÀÌ Mouth Kote-MD´Â 2021³â Parnell Pharmaceuticals, Inc.¿¡¼­ ¹ßÇ¥Çß½À´Ï´Ù.

¿¬·É´ëº°·Î º¼ ¶§ ½ÃÀåÀº ¼ºÀΰú ¼Ò¾Æ·Î À̺е˴ϴÙ. ÀÌ Áß ¼ºÀÎ Ä«Å×°í¸®°¡ 2020³â Àΰø Ÿ¾× ½ÃÀåÀÇ ¼ºÀåÀ» Áö¹èÇß½À´Ï´Ù. ÀÌ´Â ÁÖ·Î Àΰø Ÿ¾×ÀÌ ¼ºÀΠȯÀÚ¿¡°Ô ´õ ¸¹ÀÌ »ç¿ëµÇ±â ¶§¹®À̸ç, ±¸°­ °ÇÁ¶ÁõÀº ÀϹÝÀûÀ¸·Î ¼Ò¾Æ ȯÀÚº¸´Ù ¼ºÀΠȯÀÚ¿¡°Ô ´õ ÈçÇϱ⠶§¹®¿¡ Á¶¸¸°£ º¯°æ µÉ °¡´É¼ºÀÌ ³·½À´Ï´Ù.

ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀÇ ¶Ç ´Ù¸¥ ¿äÀÎÀº ±¸°­¾Ï°ú ½Äµµ¾ÏÀ¸·Î ÀÎÇÑ »ïŰ´Â Àå¾Ö Áõ°¡ÀÔ´Ï´Ù. ¿¹¸¦ µé¾î ¼¼°è¾Ï ¿¬±¸±â±Ý(WCRF International)¿¡ µû¸£¸é 2020³â¿¡´Â ¾à 60¸¸ 4,100°ÇÀÇ ½Äµµ¾ÏÀÌ »õ·Ó°Ô Áø´ÜµÇ¾ú½À´Ï´Ù.

Àΰø Ÿ¾× ½ÃÀåÀº À¯Åë ä³Îº°·Î º´¿ø ¾à±¹, ¼Ò¸Å ¾à±¹, ½´ÆÛ¸¶ÄÏ ¹× ÇÏÀÌÆÛ¸¶ÄÏ µîÀ¸·Î ºÐ·ùµË´Ï´Ù. ¿¹Ãø ±â°£ Áß °¡Àå ³ôÀº ¼ºÀåÀ» ÀÌ·ç´Â °ÍÀº ¼Ò¸Å ¾à±¹ÀÔ´Ï´Ù. À̰ÍÀº ÁÖ·Î ÀǾàǰÀÇ Àú·ÅÇÑ °¡°Ý°ú ±¸°­ °ÇÁ¶ »óŸ¦ ÀÏÀ¸Å°´Â ´ç´¢º´, ³úÁ¹Áß, ¾ËÃ÷ÇÏÀ̸Ӻ´, ¼î±×·» ÁõÈıº, HIV/AIDSÀÇ Áõ·Ê°¡ Áõ°¡ÇÏ´Â Àα¸ Áõ°¡ ¶§¹®ÀÔ´Ï´Ù. ¿¹¸¦ µé¾î ±¹Á¦ ´ç´¢º´ ¿¬ÇÕ(IDF)¿¡ µû¸£¸é 2021³â¿¡´Â ¾à 120¸¸ ¸íÀÇ Ã»¼Ò³â°ú û¼Ò³âÀÌ 1Çü ´ç´¢º´À» ¾Î°í ÀÖ½À´Ï´Ù.

Àΰø Ÿ¾× »ê¾÷ÀÇ ½ÃÀå µµÀÔ¿¡ ´ëÇÑ ÀÌÇØ¸¦ ³ôÀ̱â À§ÇØ ½ÃÀåÀº ºÏ¹Ì(¹Ì±¹, ij³ª´Ù, ±âŸ ºÏ¹Ì Áö¿ª), À¯·´(µ¶ÀÏ, ¿µ±¹, ÇÁ¶û½º, ½ºÆäÀÎ, ÀÌÅ»¸®¾Æ, ±âŸ À¯·´ Áö¿ª), ¾Æ½Ã¾Æ ÅÂÆò¾ç(Áß±¹, ÀϺ», Àεµ, ±âŸ ¾Æ½Ã¾Æ ÅÂÆò¾ç) ¹× ±âŸ ±¹°¡¿Í °°Àº Àü ¼¼°è ±¹°¡¿¡¼­ÀÇ ÀÔÁö¸¦ ±â¹ÝÀ¸·Î ºÐ¼®µË´Ï´Ù. ºÏ¹Ì´Â ¿¹Ãø ±â°£ Áß »ó´çÇÑ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ´Â ÁÖ·Î ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷ÀÌ Á¸ÀçÇϰí, ±¸°­ Áúȯ¿¡ ´ëÇÑ ÀǽÄÀÌ ³ô¾ÆÁö°í ÀÖ´Â °Í, ±¸°­ °ÇÁ¶ÁõÀ» Ä¡·áÇϱâ À§ÇÑ Á¦Ç° ÀÌ¿ëÀÌ Áõ°¡Çϰí ÀÖ´Â °Í, °¡Ã³ºÐ ¼ÒµæÀÌ Áõ°¡Çϰí ÀÖ´Â °Í , ¾ÏÀ̳ª ¾ËÃ÷ÇÏÀ̸Ӻ´ÀÇ À¯º´·üÀÌ Áõ°¡Çϰí ÀÖ´Â °Í, ±â¼úÀû Áøº¸°¡ ÁøÇàµÇ°í ÀÖ´Â °Í, ȯÀÚ Àα¸°¡ ¸¹Àº °Í µîÀÌ ¿äÀÎÀ̸ç, ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î ±¹¸³ ¸¸¼ºÁúȯ ¿¹¹æ ¼¾ÅÍ(CDC)¿¡ µû¸£¸é 2020³â¿¡´Â 580¸¸ ¸íÀÇ ¹Ì±¹ÀÎÀÌ ¾ËÃ÷ÇÏÀ̸Ӻ´À» ¾Î°í ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ½ÃÀå ¼Ò°³

  • ½ÃÀå Á¤ÀÇ
  • ÁÖ¿ä ¸ñÀû
  • ÀÌÇØ°ü°èÀÚ
  • Á¦ÇÑ »çÇ×

Á¦2Àå Á¶»ç ¹æ¹ý ¶Ç´Â ÀüÁ¦

  • Á¶»ç ÇÁ·Î¼¼½º
  • Á¶»ç ¹æ¹ý
  • ÀÀ´äÀÚ °³¿ä

Á¦3Àå ½ÃÀå ¿ä¾à

Á¦4Àå ÁÖ¿ä ¿ä¾à

Á¦5Àå COVID-19°¡ Àΰø Ÿ¾× ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâ

Á¦6Àå Àΰø Ÿ¾× ½ÃÀå ¸ÅÃâ(2020-2028³â)

Á¦7Àå Á¦Ç° À¯Çüº° ½ÃÀå ÀλçÀÌÆ®

  • °æ±¸ ½ºÇÁ·¹ÀÌ
  • °æ±¸¾×
  • ³»º¹¾×
  • °Ö
  • ºÐ¸»

Á¦8Àå ¿¬·ÉÃþº° ½ÃÀå ÀλçÀÌÆ®

  • ¼ºÀÎ
  • ¼Ò¾Æ

Á¦9Àå À¯Åë ä³Îº° ½ÃÀå ÀλçÀÌÆ®

  • º´¿ø ¾à±¹
  • ¼Ò¸Å ¾à±¹
  • ±âŸ

Á¦10Àå Áö¿ªº° ½ÃÀå ÀλçÀÌÆ®

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
    • ±âŸ ºÏ¹Ì Áö¿ª
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ±âŸ À¯·´ Áö¿ª
  • ¾Æ½Ã¾Æ ÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • ±âŸ ¾Æ½Ã¾Æ ÅÂÆò¾ç
  • ±âŸ ¼¼°è Áö¿ª

Á¦11Àå Àΰø Ÿ¾× ½ÃÀå ¿ªÇÐ

  • ½ÃÀå ÃËÁø ¿äÀÎ
  • ½ÃÀåÀÌ ÇØ°áÇØ¾ß ÇÒ °úÁ¦
  • ¿µÇ⠺м®

Á¦12Àå Àΰø Ÿ¾× ½ÃÀå ±âȸ

Á¦13Àå Àΰø Ÿ¾× ½ÃÀå µ¿Çâ

Á¦14Àå ¼ö¿ä ¹× °ø±ÞÃø ºÐ¼®

  • ¼ö¿äÃø ºÐ¼®
  • °ø±ÞÃø ºÐ¼®

Á¦15Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦16Àå °¡°Ý ºÐ¼®

Á¦17Àå Àü·«Àû ÀλçÀÌÆ®

Á¦18Àå °æÀï ½Ã³ª¸®¿À

  • °æÀï »óȲ
    • Porter's Five Forces ºÐ¼®

Á¦19Àå ±â¾÷ °³¿ä

  • GSK plc.
  • Cipla Inc.
  • Mission Pharmacal Company
  • Fresenius Kabi AG
  • Parnell Pharmaceuticals, Inc.
  • CCMed Ltd.
  • ENTOD INTERNATIONAL
  • Midatech Pharma PLC
  • Forward Science
  • Bausch Health Companies Inc.

Á¦20Àå ¸éÃ¥»çÇ×

LYJ 23.09.05

Chewing, swallowing, digesting, and speaking all depend on saliva. Additionally, it controls bacteria growth in the mouth & reducing the risk of infection and tooth decay. While primarily water, natural saliva also contains mucous, enzymes, and electrolytes. Although artificial saliva doesn't exactly like the saliva that our glands normally create, the combination of its ingredients can help relieve symptoms like bad breath and a feeling of dryness or stickiness in the mouth.

Also, doctors may recommend the use of artificial saliva alongside medications and medical treatments, such as pain medications and chemotherapy, that are known to cause dry mouth. For instance, according to the National Cancer Institute (NIH), in 2022, it is estimated that there are 18.1 million cancer survivors in the United States. This represents approximately 5.4% of the population and it is projected to increase by 24.4%, to 22.5 million, by 2032.

The artificial saliva market is expected to grow at a steady rate of around 13% owing to the increasing prevalence of dysphagia condition in cancer patients. Also, the expensive treatments for oral diseases in both developed & developing countries and the growing disposable income and increasing per-capita spending drive the growth of the market during the forecast period.

Based on product type, the market is segmented into oral spray, oral solution, oral liquid, gel, and powder. The oral spray category is to witness the highest CAGR during the forecast period. This is mainly due to their ease of use, efficiency & low cost, and these sprays are commonly used to treat dry mouth conditions. Also, increasing product development by key players drives the growth of the segment. For instance, Mouth Kote-MD, a mouth spray based on MycoDelens, a proprietary substance created and licensed by New Mexico Tech University, was presented by Parnell Pharmaceuticals, Inc. in 2021.

On the basis of age group, the market is bifurcated into adult and pediatric. Among these, the adult category dominated the growth of the artificial saliva market in 2020. This is mainly due to the artificial saliva being used more by adult patients and this is unlikely to change anytime soon as the dry mouth condition is typically more common in adult patients than pediatric ones.

The other factor for the growth of this segment is the growing dysphagia condition due to mouth cancer or oesophageal cancer. For instance, according to the World Cancer Research Fund (WCRF International), around 604,100 new cases of oesophageal cancer were diagnosed in 2020.

Based on distribution channel, the artificial saliva market has been classified into hospital pharmacies, retail pharmacies, supermarkets & hypermarkets, and others. The retail pharmacies category is to witness the highest growth during the forecast period. This is mainly due to the affordability of medicines and the growing population with rising cases of diabetes, stroke, Alzheimer's disease, Sjogren's syndrome, or HIV/AIDS which will cause dry mouth conditions. For instance, as per the International Diabetes Federation (IDF), around 1.2 million youngsters and youths have type 1 diabetes in 2021.

For a better understanding of the market adoption of the artificial saliva industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America is anticipated to grow at a substantial CAGR during the forecast period. This is mainly due to the availability of major market key players, rising awareness about oral diseases, growing product utilization to treat xerostomia, rising disposable incomes, increasing prevalence of cancer and Alzheimer's disease, growing technological advancements, and presence of a large patient population in the region, which is expected to aid the market growth. For instance, according to the National Center for Chronic Disease Prevention (CDC), in 2020, as many as 5.8 million Americans were living with Alzheimer's disease.

Some of the major players operating in the market include: GSK plc.; Cipla Inc.; Mission Pharmacal Company; Fresenius Kabi AG; Parnell Pharmaceuticals, Inc.; CCMed Ltd.; ENTOD INTERNATIONAL; Midatech Pharma PLC; Forward Science; Bausch Health Companies Inc.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

  • 1.1. Market Definitions
  • 1.2. Main Objective
  • 1.3. Stakeholders
  • 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

  • 2.1. Research Process of the Artificial Saliva Market
  • 2.2. Research Methodology of the Artificial Saliva Market
  • 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE ARTIFICIAL SALIVA MARKET

6 ARTIFICIAL SALIVA MARKET REVENUE, 2020-2028F

7 MARKET INSIGHTS BY PRODUCT TYPE

  • 7.1. Oral Spray
  • 7.2. Oral Solution
  • 7.3. Oral Liquid
  • 7.4. Gel
  • 7.5. Powder

8 MARKET INSIGHTS BY AGE GROUP

  • 8.1. Adult
  • 8.2. Paediatric

9 MARKET INSIGHTS BY DISTRIBUTION CHANNEL

  • 9.1. Hospital Pharmacies
  • 9.2. Retail Pharmacies
  • 9.3. Others

10 MARKET INSIGHTS BY REGION

  • 10.1. North America
    • 10.1.1. U.S.
    • 10.1.2. Canada
    • 10.1.3. Rest of North America
  • 10.2. Europe
    • 10.2.1. Germany
    • 10.2.2. U.K.
    • 10.2.3. France
    • 10.2.4. Italy
    • 10.2.5. Spain
    • 10.2.6. Rest of Europe
  • 10.3. Asia-Pacific
    • 10.3.1. China
    • 10.3.2. Japan
    • 10.3.3. India
    • 10.3.4. Rest of Asia-Pacific
  • 10.4. Rest of World

11 ARTIFICIAL SALIVA MARKET DYNAMICS

  • 11.1. Market Drivers
  • 11.2. Market Challenges
  • 11.3. Impact Analysis

12 ARTIFICIAL SALIVA MARKET OPPORTUNITIES

13 ARTIFICIAL SALIVA MARKET TRENDS

14 DEMAND AND SUPPLY-SIDE ANALYSIS

  • 14.1. Demand Side Analysis
  • 14.2. Supply Side Analysis

15 VALUE CHAIN ANALYSIS

16 PRICING ANALYSIS

17 STRATEGIC INSIGHTS

18 COMPETITIVE SCENARIO

  • 18.1. Competitive Landscape
    • 18.1.1. Porters Fiver Forces Analysis

19 COMPANY PROFILED

  • 19.1. GSK plc.
  • 19.2. Cipla Inc.
  • 19.3. Mission Pharmacal Company
  • 19.4. Fresenius Kabi AG
  • 19.5. Parnell Pharmaceuticals, Inc.
  • 19.6. CCMed Ltd.
  • 19.7. ENTOD INTERNATIONAL
  • 19.8. Midatech Pharma PLC
  • 19.9. Forward Science
  • 19.10. Bausch Health Companies Inc.

20 DISCLAIMER

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦